On page 786 in the 22 January 2009 issue, there is an error in the P value required for significance, which reads “of less than .001.” The correct P value is “of less than 2.9 × 10−4.” In the “Methods” section, the fourth sentence under the heading “Statistical analysis” reads, “Meff was 172 in our study and hence a P value of less than .001 was required for significance.” The sentence should have read, “Meff was 172 in our study and hence a P value of less than 2.9 × 10−4 was required for significance.”
On page 788, there is an error in the TIR calculations. The “Results” section, under the heading, “Time in range,” reads, “During the first 3 months, the median time in range, 2 to 3 (TIR), was 67% (average, 65%). VKORC1 rs9923231 G>A had a nominal effect on TIR during the first 3 months (P = .003, and for rs2359612 C>T P = .002). Average TIR was the highest (70%) in A/A individuals (in LD with rs2359612 T/T) and the lowest (64%) in G/G individuals (in LD with rs2359612 C/C). CYP2C9*2 and *3 also nominally affected this outcome (P = .041). TIR was the lowest in *3/*3 individuals (average, 53%), and relatively high in *2/*3 heterozygotes (average 67% to 72%). After correction for multiple testing (P < .001), no candidate gene was significantly associated with TIR during the first 3 months.
“The median time in range 2 to 3 during the entire treatment period was 64% (average, 61%). When the 39 patients with a target INR outside 2.4 to 2.6 were removed, the overall average TIR increased by 0.1%. VKORC1 rs9923231 was significantly associated with overall time in range (P = 1.68 × 10−4, and for rs2359612 P = 1.47 × 10−4). As above, average TIR was the highest (65%) in A/A individuals (rs2359612 T/T) and the lowest (60%) in rs9923231 G/G individuals (rs2359612 C/C). NR1I3 SNP rs3003596 was almost significantly associated with overall TIR after correction for multiple testing (P = .001). CYP2C9 was not associated with overall TIR.”
The content should have read, “During the first 3 months, the median time in range, 2.0 to 3.0 (TIR), was 70% (average, 67%). VKORC1 rs9923231 G>A had a nominal effect on TIR during the first 3 months (P = .004, and for rs2359612 C>T P = .001). Average TIR was the highest (71%) in A/A individuals (in LD with rs2359612 T/T) and the lowest (65%) in G/G individuals (in LD with rs2359612 C/C). CYP2C9*2 and *3 also affected this outcome (P = .001). TIR was the lowest in *3/*3 individuals (average, 50%), and relatively high in *2/*3 heterozygotes (average 69% to 71%). After correction for multiple testing (P < 2.9 × 10−4), no candidate gene was significantly associated with TIR during the first 3 months.
“The median time in range 2.0 to 3.0 during the entire treatment period was 74% (average, 71%). VKORC1 rs9923231 was significantly associated with overall time in range (P = .001, and for rs2359612 P = 7.45 × 10−4). As above, average TIR was the highest (75%) in A/A individuals (rs2359612 T/T) and the lowest (69%) in rs9923231 G/G individuals (rs2359612 C/C). CYP2C9*2 and *3 was associated with overall TIR (P = .002). TIR was again lowest in *3/*3 individuals (average, 58%) and highest in *2/*3 heterozygotes (mean, 73% for all). After correction for multiple testing (P < 2.9 × 10−4), no candidate gene was significantly associated with overall TIR.”
